Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability

Journal of Intellectual Disability Research

Volumn 44, Issue 2, 2000, Pages 164-169

  Williams, H ^a   Clarke, R ^a   Bouras, N ^a   Martin, J ^a   Holt, Geraldine ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Antipsychotics; Atypical; Mental health problems; Olanzapine; Risperidone

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELUSION; DRUG EFFICACY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; MALE; MENTAL DEFICIENCY; MENTAL DISEASE; NEUROSIS; PSYCHOSIS; RASH; SCHIZOPHRENIA; TREMOR;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL RETARDATION; MIDDLE AGED; MOOD DISORDERS; PIRENZEPINE; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; QUESTIONNAIRES; RISPERIDONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0034042859     PISSN: 09642633     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2788.2000.00284.x     Document Type: Article

References (16)

1. Baumeister A., Seven J. A. & King B. H. (1998) Neuroleptics. In: Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook (eds A. Reiss & M. G. Aman), pp. 133-50. The Ohio State University Press, Columbus, OH.
2. British National Formulary (1999) BMJ Books, London.
3. Cohen S. A., Ihrig K., Lott R. S. & Kerrick J. M. (1998) Risperidone for aggression and self-injurious behavior in adults with mental retardation. Journal of Autism and Developmental Disorders 28, 229-33.
4. Connor D. F. & Posever T. A. (1998) A brief review of atypical antipsychotics in individuals with developmental disability. Mental Health Aspects of Developmental Disabilities 4, 93-102.
5. Glazer W. M. (1997) Olanzapine and the new generation of antipsychotic agents: patterns of use. Journal of Clinical Psychiatry 58, 18-21.
6. Guy W. (1976) Assessment Manual for Psychopharmacology. Publication 76-338, National Institute of Mental Health, US Department of Health, Education and Welfare, Washington, DC.
7. Horrigan J. P., Barnhill L. J. & Courvoisie H. E. (1997) Olanzapine in PDD. Journal of the American Academy of Child and Adolescent Psychiatry 36, 1166-7.
8. Kiernan C., Reeves D. & Alborz A. (1995) The use of antipsychotic drugs with adults with learning disabilities and challenging behaviour. Journal of Intellectual Disability Research 39, 263-74.
9. McDougle C. J., Holmes J. P., Carlson D. C., Pelton G. H., Cohen D. J. & Price L. H. (1998) A double blind study placebo controlled of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry 55, 633-41.
10. Reus V. I. (1997) Olanzapine: a novel atypical neuroleptic agent. The Lancet 349, 1264-5.
11. Rinck C. (1998) Epidemiology and psychoactive medication. In: Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook (eds A. Reiss & M. G. Aman), pp. 31-44. The Ohio State University Press, Columbus, OH.
12. Thomas C. S. & Lewis S. (1998) Which atypical antipsychotic? British Journal of Psychiatry 172, 106-9.
13. Tollefson G. D. & Kuntz A. J. (1999) Recent clinical studies with olanzapine. British Journal of Psychiatry 174 (Suppl. 37), 30-5.
14. Tran P. V., Hamilton S. H., Kuntz A. J., Potvin J. H., Anderson S. W., Beasky Jr C. & Tollefson G. D. (1997) Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 17, 407-18.
15. Vanden Borre V., Vermote R., Buttiens M., Thiry P., Dierick G., Geutjens J., Sieben G. & Heylen S. (1993) Risperidone as a add cm therapy in behavioural disturbances in mental retardation: a double-blind placebo controlled cross-over study. Acta Psychiatrica Scandinavia 87, 167-71.
16. Wilson J. G., Lott R. S. & Tsai L. (1998) Side effects: recognition and management. In: Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook (eds A. Reiss & M. G. Aman), pp. 95-114. The Ohio State University Press, Columbus, OH.